Unravel Biosciences
Unravel Biosciences uses patient RNA data and AI to rapidly identify and validate drug targets for complex and rare disorders in plain terms. The company combines a proprietary foundation model of human health with systems biology and in-silico network analysis, integrated with RNA sequencing, rapid in vivo (animal) model generation, and clinical validation to repurpose existing drugs against newly discovered mechanisms. Unravel operates as a therapeutics developer and service provider, offering discovery platform capabilities, rareSHIFT sequencing and repurposing services, and licensing partnerships to biopharma companies and foundations. Its platform has produced multiple clinical programs, including an orphan-designated Rett syndrome program entering trials, and supports faster translation of discoveries into clinical testing.
Unravel Biosciences
Unravel Biosciences uses patient RNA data and AI to rapidly identify and validate drug targets for complex and rare disorders in plain terms. The company combines a proprietary foundation model of human health with systems biology and in-silico network analysis, integrated with RNA sequencing, rapid in vivo (animal) model generation, and clinical validation to repurpose existing drugs against newly discovered mechanisms. Unravel operates as a therapeutics developer and service provider, offering discovery platform capabilities, rareSHIFT sequencing and repurposing services, and licensing partnerships to biopharma companies and foundations. Its platform has produced multiple clinical programs, including an orphan-designated Rett syndrome program entering trials, and supports faster translation of discoveries into clinical testing.